<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849196</url>
  </required_header>
  <id_info>
    <org_study_id>2017-05-100</org_study_id>
    <nct_id>NCT03849196</nct_id>
  </id_info>
  <brief_title>Effectiveness of Bisacodyl Suppository Agent for Dose Reduction of Low Dose PEG</brief_title>
  <official_title>Simultaneous Combination of Bisacodyl Suppository Agent and 1L Polyethylene Glycol Plus Ascorbic Acid is Not Inferior and Comfortable Regimen Compared With 2L Polyethylene Glycol Plus Ascorbic Acid: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proper bowel cleansing before colonoscopy is an important factor to increase the detection
      rate of lesions. Low volume polyethylene glycol (PEG) plus ascorbic (PEG-Asc) has reduced the
      dosage of previous bowel preparation agent, but it still presents discomfort to patients. The
      aim of this study was to confirm the efficacy and convenience of volume reduction of PEG-Asc
      by adding bisacodyl suppository at the same day by compared with conventional 2L PEG-Asc.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility criteria: outpatients between the ages of 20 and 70 years, who were scheduled for
      colonoscopy between August 2017 and January 2018

      Exclusion criteria: patients with a history of gastrointestinal tract surgery, inflammatory
      bowel disease, severe active colitis, underlying chronic kidney disease, or pregnancy.

      Outcome measures: the Boston Bowel Preparation Scale (BBPS)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Actual">January 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective, randomized, and observer-blind study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Boston Bowel Preparation Scale (BBPS).</measure>
    <time_frame>1 hour</time_frame>
    <description>4-point scoring system (0-3) applied to each of the 3 colon segments (right colon including cecum and ascending colon, transverse colon including transverse colon, hepatic and splenic flexure, left colon including descending colon, sigmoid colon, and rectum)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Bowel Preparation</condition>
  <arm_group>
    <arm_group_label>2L PEG-Asc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2L PEG-Asc for bowel preparation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1L PEG-Asc &amp; 'Bisacodyl 10Mg Suppository</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1L PEG-Asc with 'Bisacodyl 10Mg Suppository for bowel preparation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2L PEG-Asc</intervention_name>
    <description>PEG-Asc powder</description>
    <arm_group_label>2L PEG-Asc</arm_group_label>
    <other_name>clicool</other_name>
    <other_name>coolprep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisacodyl 10Mg Suppository</intervention_name>
    <description>bisacodyl 10 mg suppository</description>
    <arm_group_label>1L PEG-Asc &amp; 'Bisacodyl 10Mg Suppository</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1L PEG-Asc</intervention_name>
    <description>PEG-Asc powder</description>
    <arm_group_label>1L PEG-Asc &amp; 'Bisacodyl 10Mg Suppository</arm_group_label>
    <other_name>clicool</other_name>
    <other_name>coolprep</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  outpatients who were scheduled for colonoscopy between August 2017 and January 2018

        Exclusion Criteria:

          -  History of gastrointestinal tract surgery

          -  History of inflammatory bowel disease

          -  History of severe active colitis

          -  History of chronic kidney disease

          -  pregnant woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>brian.biochem@gmail.com Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 16, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Eun Ran Kim</investigator_full_name>
    <investigator_title>Clinical associate professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisacodyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

